Alkermes (NASDAQ:ALKS) Updates FY 2025 Earnings Guidance

Alkermes (NASDAQ:ALKS) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.030-1.210 for the period, compared to the consensus earnings per share estimate of 1.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. HC Wainwright restated a “neutral” rating and set a $46.00 target price on shares of Alkermes in a research report on Thursday. Mizuho raised their price objective on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. StockNews.com raised Alkermes from a “buy” rating to a “strong-buy” rating in a research note on Thursday. JPMorgan Chase & Co. lowered their price objective on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, Cantor Fitzgerald lowered their target price on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.25.

Alkermes Stock Up 0.1 %

Shares of ALKS traded up $0.04 on Friday, hitting $36.04. 73,198 shares of the stock traded hands, compared to its average volume of 1,645,947. The company has a market capitalization of $5.83 billion, a PE ratio of 18.46, a P/E/G ratio of 1.83 and a beta of 0.49. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45. The business has a 50 day simple moving average of $30.31 and a 200 day simple moving average of $28.73. Alkermes has a one year low of $22.90 and a one year high of $36.14.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 22.15% and a return on equity of 24.92%. As a group, equities analysts forecast that Alkermes will post 2.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Craig C. Hopkinson sold 100,918 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the completion of the sale, the executive vice president now owns 44,290 shares of the company’s stock, valued at $1,419,494.50. The trade was a 69.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Cato T. Laurencin sold 2,691 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $31.85, for a total transaction of $85,708.35. Following the sale, the director now directly owns 23,013 shares of the company’s stock, valued at approximately $732,964.05. The trade was a 10.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 179,189 shares of company stock valued at $5,723,518. Company insiders own 4.89% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.